Mayra Cantazaro
Family · Edinburg, TXNPI 1619386190
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,256 of the $150,429 with a category attached, or 73.3%. Novo Nordisk accounts for 89.2% of it on its own, with 28 other manufacturers making up the rest. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 526 payments — averaging $285.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$134K
- Mannkind Corporation$8K
- Medtronic$2K
- Dexcom, Inc.$2K
- AstraZeneca$804
- Corcept Therapeutics$673
- plus $4K from 23 others
What the payments were for
- Consulting fees$10,2047%
- Speaking & faculty fees$110,25673%
- Travel & lodging$15,99411%
- Food & beverage$13,8799%
- Education$120%
- Gifts$590%
- Entertainment$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 227 | $134,110 |
| Mannkind Corporation | 54 | $7,673 |
| Medtronic | 17 | $1,972 |
| Dexcom, Inc. | 50 | $1,508 |
| AstraZeneca(2 entities) | 8 | $804 |
| Corcept Therapeutics | 34 | $673 |
| Amgen(2 entities) | 12 | $399 |
| Lilly USA, LLC | 20 | $398 |
| Intuity Medical Inc | 11 | $397 |
| Ascensia Diabetes Care US Inc. | 7 | $374 |
| Insulet Corporation | 6 | $268 |
| Tandem Diabetes Care, Inc. | 7 | $253 |
| Abbott | 12 | $250 |
| Bayer | 6 | $217 |
| Xeris Pharmaceuticals, Inc. | 10 | $193 |
| Novartis | 8 | $166 |
| Radius Health, Inc. | 7 | $144 |
| Boehringer Ingelheim | 5 | $107 |
| Averitas Pharma Inc. | 5 | $96 |
| Cequr Corporation | 3 | $76 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Chiesi USA, Inc. | 2 | $43 |
| Madrigal Pharmaceuticals | 1 | $43 |
| Amryt Pharma Holdings Ltd | 2 | $36 |
| Antares Pharma, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$78,154
- Ozempic$38,458
- AFREZZA$6,433
- MINIMED 780G$1,378
- FARXIGA$749
- DEXCOM G6 TRANSMITTER$699
- EVERSENSE E3 SENSOR KIT - RETAIL$268
- Korlym$216
- Omnipod$129
- Pogo Automatic Blood Glucose Monitoring System$126
- Kerendia$125
- V-GO$125
- Wegovy$125
- t:slim X2 Insulin Pump with Control-IQ$122
How this compares
$150,429 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 574 | $784,428 |
| MounjaroTirzepatide | 280 | $359,475 |
| JardianceEmpagliflozin | 180 | $224,267 |
| Tresiba Flextouch U-200Insulin Degludec | 171 | $194,536 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 160 | $178,540 |
| FarxigaDapagliflozin Propanediol | 150 | $146,674 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 87 | $100,587 |
| AfrezzaInsulin Regular, Human | 35 | $87,868 |
| Xigduo XrDapaglifloz Propaned/Metformin | 59 | $60,980 |
| RybelsusSemaglutide | 44 | $59,587 |
| Gvoke Hypopen 2-PackGlucagon | 84 | $55,155 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 36 | $45,218 |
| TradjentaLinagliptin | 45 | $34,322 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $31,855 |
| Repatha SyringeEvolocumab | 34 | $28,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $134,110 | $848,006643 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $107 | $453,618407 claims |
| Lilly USA, LLCMounjaro, Trulicity | $398 | $385,106298 claims |
| AstraZenecaFarxiga | $804 | $146,674150 claims |
| Mannkind CorporationAfrezza | $7,673 | $87,86835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Edinburg
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.